|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Feb 1, 2025
|
FY2024
12 months to Feb 3, 2024
|
FY2023
12 months to Jan 28, 2023
|
FY2022
12 months to Jan 29, 2022
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net earnings | |||||
| Adjustments to reconcile net earnings to total cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Restructuring charges | |||||
| Goodwill impairment | |||||
| Goodwill and intangible asset impairments | |||||
| Stock-based compensation | |||||
| Deferred income taxes | |||||
| Gain on sale of subsidiary, net | |||||
| Long-lived asset impairments | |||||
| Other, net | |||||
| Changes in operating assets and liabilities: | |||||
| Receivables | |||||
| Merchandise inventories | |||||
| Other assets | |||||
| Accounts payable | |||||
| Income taxes | |||||
| Other liabilities | |||||
| Total cash provided by operating activities | |||||
| Investing activities | |||||
| Additions to property and equipment | |||||
| Purchases of investments | |||||
| Net proceeds from sale of subsidiary | |||||
| Disposal of subsidiary | |||||
| Sales of investments | |||||
| Other, net | |||||
| Total cash used in investing activities | |||||
| Financing activities | |||||
| Repurchase of common stock | |||||
| Issuance of common stock | |||||
| Dividends paid | |||||
| Repayments of debt | |||||
| Other, net | |||||
| Total cash used in financing activities | |||||
| Effect of exchange rate changes on cash | |||||
| Increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Supplemental cash flow information | |||||
| Income taxes paid (includes payments for purchased tax credits of $150 million, $267 million and $103 million, respectively) | |||||
| Interest paid | |||||
Loading...
